BioSpace News Archive

The American Diabetes Association® welcomes the 2022 Principal Officers and Board of Directors.

Milestone Scientific Inc. today reported, that following a successful trial, it has signed an agreement for the purchase of its CompuFlo ® Epidural and CathCheck ™ Verification System disposables with a major Northeast teaching hospital, which is part of one of the leading health systems in the United States.

Aerie Pharmaceuticals, Inc. reports an inducement grant to Chief Executive Officer, Raj Kannan, appointed on December 16, 2021 with a start date of December 20, 2021.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Leqvio® (inclisiran), the fourth small interfering RNA (siRNA) therapy (or RNAi therapeutic) approved in the U.S., and the first and only to lower low-density lipoprotein cholesterol (also known as “bad cholesterol” or LDL-C).

Cronus Pharma LLC announced Mr. Todd Brodersen has joined as Senior Director of Sales & Marketing.

Leonhardt Ventures LLC, a pioneer in developing bioelectric and biologic innovations for organ regeneration and healing, today announced that the U.S. Patent and Trademark Office issued a pioneering U.S. patent for its novel multi-modality bioelectric stimulation system for treating cancer.

According to Yiling Pharmaceutical’s notice on Thursday (UTC+8) , the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued by China’s National Medical Products Administration (NMPA).

CureDuchenne Ventures announces a $1 million investment in Gennao Bio’s Series A extension to help the company apply their gene monoclonal antibody (GMAB) platform technology to Duchenne muscular dystrophy (DMD) and other rare muscle diseases.

Akeso, Inc. announces that Ebronucimab, jointly developed by the Company and Dawnrays Biotechnology Capital Ltd., completed patient enrollment early in a pivotal registrational phase III clinical trial in the People’s Republic of China for the treatment of primary hypercholesterolemia and mixed hyperlipidemia.

Transparency Market Research has published a new report on the Soft tissue allografts market for the forecast period of 2019–2027.